EASTYLE (DE-escAlation Strategy for Optimal Ticagrelor Therapy in Acute MYocardiaL Infarction PatiEnts, Prospective, Multicenter, Randomized) Trial
Who is this study for? Patients with Myocardial Infarction
What treatments are being studied? Ticagrelor
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 80
Healthy Volunteers: f
View:
• Diagnosis with acute myocardial infarction.
• Age ≥19 year-old
• Successful PCI with ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).
• Provision of informed consent.
Locations
Other Locations
Republic of Korea
DongA University Hospital
RECRUITING
Busan
Contact Information
Primary
Moo Hyun Kim, MD, PhD
kimmh@dau.ac.kr
+82-51-240-2976
Backup
Young-Hoon Jeong, MD, PhD
goodoctor@naver.com
+82-2-2610-6795
Time Frame
Start Date: 2023-03-27
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 2312
Treatments
Experimental: De-escalation strategy
PCI \~ 1 month: ticagrelor 90 mg twice daily + aspirin 100 mg once daily~1 \~ 3 months: ticagrelor 60 mg twice daily + aspirin 100 mg once daily~3 \~ 12 months: ticagrelor 60 mg twice daily
Active_comparator: Conventional strategy
PCI \~ 12 months: ticagrelor 90 mg twice daily + aspirin 100 mg once daily
Authors
Related Therapeutic Areas
Sponsors
Collaborators: Samjin Pharmaceutical Co., Ltd., Biotronik SE & Co. KG
Leads: Dong-A University